Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 3/20 | 1.00 |
| ▸ | CRHR2 | Q13324 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.77 |
| ▸ | NAT1 | P18440 | 5/20 | 0.66 |
| ▸ | MYC | P01106 | 3/20 | 0.66 |
| ▸ | MAX | P61244 | 3/20 | 0.66 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194557 | 1.00 | CRHBP (1.00) | CRHBPCRHR2PIM1PIM2NAT1 | |
| SCHEMBL194558 | 1.00 | CRHBP (1.00) | CRHBPCRHR2PIM1PIM2NAT1 | |
| SCHEMBL14891689 | 0.91 | CRHBP (0.90) | CRHBPCRHR2PIM1PIM2NAT1 | |
| SCHEMBL14891688 | 0.91 | CRHBP (0.90) | CRHBPCRHR2PIM1PIM2NAT1 | |
| SCHEMBL1248777 | 0.87 | PIM1 (1.00) | CRHBPCRHR2PIM1PIM2CISD1 | |
| SCHEMBL2544392 | 0.87 | PIM1 (1.00) | CRHBPCRHR2PIM1PIM2CISD1 | |
| SCHEMBL1248775 | 0.87 | PIM1 (1.00) | CRHBPCRHR2PIM1PIM2CISD1 | |
| SCHEMBL24991948 | 0.84 | CRHBP (0.73) | CRHBPCRHR2PIM1PIM2NAT1 | |
| SCHEMBL1249353 | 0.84 | CRHBP (1.00) | CRHBPCRHR2NAT1MYCMAX | |
| SCHEMBL194498 | 0.84 | CRHBP (1.00) | CRHBPCRHR2NAT1MYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252040-B1 | STABILIZER FOR PRESERVING BIOLOGICAL SAMPLES | BGI SHENZHEN (CN) | 2023-04-19 | — | — | EP | claimed |
| US-10494661-B2 | Stabilizer for preserving biological samples | BGI SHENZHEN (CN) | 2019-12-03 | — | — | US | claimed |
| US-20180334703-A1 | Stabilizer for Preserving Biological Samples | BGI SHENZHEN (CN) | 2018-11-22 | — | — | US | claimed |
| EP-3252040-A1 | STABILIZER FOR PRESERVING BIOLOGICAL SAMPLES | BGI Shenzhen (CN) | 2017-12-06 | — | — | EP | claimed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | claimed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | claimed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | claimed |
| EP-3252040-B1 | STABILIZER FOR PRESERVING BIOLOGICAL SAMPLES | BGI SHENZHEN (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-10494661-B2 | Stabilizer for preserving biological samples | BGI SHENZHEN (CN) | 2019-12-03 | — | — | US | disclosed |
| US-20180334703-A1 | Stabilizer for Preserving Biological Samples | BGI SHENZHEN (CN) | 2018-11-22 | — | — | US | disclosed |
| EP-3252040-A1 | STABILIZER FOR PRESERVING BIOLOGICAL SAMPLES | BGI Shenzhen (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | CRHBP 77/4885CRHR2 1483/4885PIM1 4412/4885 |
| US-20180334703-A1 | Stabilizer for Preserving Biological Samples | NEFM, TREH, RNASE1 | CRHBP 648/4885CRHR2 2684/4885PIM1 1293/4885 |
| US-10494661-B2 | Stabilizer for preserving biological samples | NEFM, TREH, RNASE1 | CRHBP 648/4885CRHR2 2684/4885PIM1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.